Eliminating human tuberculosis in the twenty-first century
暂无分享,去创建一个
[1] Luca Richeldi,et al. An update on the diagnosis of tuberculosis infection. , 2006, American journal of respiratory and critical care medicine.
[2] Ted Cohen,et al. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. , 2003, The Lancet. Infectious diseases.
[3] S. Blower,et al. Quantifying the intrinsic transmission dynamics of tuberculosis. , 1998, Theoretical population biology.
[4] S. Blower,et al. Control Strategies for Tuberculosis Epidemics: New Models for Old Problems , 1996, Science.
[5] S. Kalantri,et al. New tools and emerging technologies for the diagnosis of tuberculosis: Part I. Latent tuberculosis , 2006, Expert review of molecular diagnostics.
[6] M. Raviglione. The Global Plan to Stop TB, 2006-2015. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[7] C. Murray,et al. Modeling the impact of global tuberculosis control strategies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[8] C. Schechter,et al. Interpretation of the tuberculin skin test , 1995, Journal of General Internal Medicine.
[9] Christopher Dye,et al. Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country , 1999 .
[10] M. Borgdorff,et al. New Measurable Indicator for Tuberculosis Case Detection , 2004, Emerging infectious diseases.
[11] P. Andersen,et al. The success and failure of BCG — implications for a novel tuberculosis vaccine , 2005, Nature Reviews Microbiology.
[12] B G Williams,et al. Criteria for the control of drug-resistant tuberculosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[13] J. Yim,et al. Treatment of Latent Tuberculosis Infection in Korea , 2008 .
[14] M. Uplekar,et al. WHO's new Stop TB Strategy , 2006, The Lancet.
[15] P E Fine,et al. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection , 1997, Epidemiology and Infection.
[16] P. Escalante. Tuberculosis , 1904, Annals of Internal Medicine.
[17] D. Cohn. Treatment of latent tuberculosis infection. , 2003, Seminars in respiratory infections.
[18] V. Krishna,et al. Interpretation of the tuberculin skin test. , 2009, Journal of the National Medical Association.
[19] C. Dye,et al. Targets for global tuberculosis control. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[20] M. Pai,et al. The prognosis of latent tuberculosis: can disease be predicted? , 2007, Trends in molecular medicine.
[21] G W Comstock,et al. Epidemiology of tuberculosis. , 1982, The American review of respiratory disease.
[22] C. Dye,et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. , 1999, JAMA.
[23] Richard D Moore,et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. , 2006, American journal of respiratory and critical care medicine.
[24] C. Dye. Global epidemiology of tuberculosis , 2006, The Lancet.
[25] Brian G. Williams,et al. Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis , 2002, Science.
[26] O. Diekmann,et al. Mathematical Epidemiology of Infectious Diseases: Model Building, Analysis and Interpretation , 2000 .
[27] R. May,et al. Infectious Diseases of Humans: Dynamics and Control , 1991, Annals of Internal Medicine.
[28] T. Frieden,et al. Trends in the prevalence and incidence of tuberculosis in south India. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[29] S. Blower,et al. The intrinsic transmission dynamics of tuberculosis epidemics , 1995, Nature Medicine.
[30] D. Jamison,et al. Tuberculosis -- Disease Control Priorities in Developing Countries , 2006 .
[31] J. Stockman. Effect of BCG Vaccination on Childhood Tuberculous Meningitis and Miliary Tuberculosis Worldwide: A Meta-analysis and Assessment of Cost-effectiveness , 2007 .
[32] C. Dye,et al. Tuberculosis control in the era of HIV , 2005, Nature Reviews Immunology.
[33] R. Horsburgh,et al. Priorities for the treatment of latent tuberculosis infection in the United States. , 2004, The New England journal of medicine.
[34] C. Dye,et al. The Development and Impact of Tuberculosis Vaccines , 2006, Cell.
[35] L. Tanoue. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis , 2008 .
[36] P E Fine,et al. The long-term dynamics of tuberculosis and other diseases with long serial intervals: implications of and for changing reproduction numbers , 1998, Epidemiology and Infection.
[37] John G. Bartlett. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient , 2004, The Lancet.
[38] Joshua A. Salomon,et al. World mortality in 2000: life tables for 191 countries. , 2002 .
[39] G. Bai,et al. Worldwide Emergence of Extensively Drug-resistant Tuberculosis , 2007, Emerging infectious diseases.
[40] Graham R. Stewart,et al. Tuberculosis: a problem with persistence , 2003, Nature Reviews Microbiology.
[41] Christopher Dye,et al. Prospects for worldwide tuberculosis control under the WHO DOTS strategy , 1998, The Lancet.
[42] C. Dye,et al. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness , 2006, The Lancet.
[43] Alan D. Lopez,et al. Global burden of disease and risk factors , 2006 .